Contrasting Applied Therapeutics (NASDAQ:APLT) & Immuron (NASDAQ:IMRN)

Applied Therapeutics (NASDAQ:APLT) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Applied Therapeutics and Immuron, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1	2	0	0	1.67
Immuron	1	0	0	0	1.00

Applied Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than Immuron.

Risk & Volatility

Applied Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500. Comparatively, Immuron has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.

Earnings & Valuation

This table compares Applied Therapeutics and Immuron”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1.00 million	15.86	-$105.62 million	($0.10)	-1.03
Immuron	$4.72 million	1.91	-$3.38 million	N/A	N/A

Immuron has higher revenue and earnings than Applied Therapeutics.

Profitability

This table compares Applied Therapeutics and Immuron’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Immuron	N/A	N/A	N/A

Institutional & Insider Ownership

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Immuron shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by company insiders. Comparatively, 7.0% of Immuron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

About Applied Therapeutics

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

About Immuron

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.